An Overview of the Impact of Body Mass Index on Pathological Complete Response Following Neoadjuvant Chemotherapy in Operable Breast Cancer in a Tertiary Care Centre in South India.

Autor:	Somashekhar SP; Department of Oncosurgery, Manipal Hospitals, Old Airport Road, Bengaluru, India., Jaiswal R; Department of Oncosurgery, Manipal Hospitals, Old Airport Road, Bengaluru, India., Kumar R; Department of Oncosurgery, Manipal Hospitals, Old Airport Road, Bengaluru, India., Ashok BC; Department of Plastic Surgery, Manipal Hospitals, Old Airport Road, Bengaluru, India., Rakshit S; Department of Pathology, Manipal Hospitals, Old Airport Road, Bengaluru, India., Rauthan A; Department of Medical Oncology, Manipal Hospitals, Old Airport Road, Bengaluru, India., Patil P; Department of Medical Oncology, Manipal Hospitals, Old Airport Road, Bengaluru, India., Yashas N; Department of Medical Oncology, Manipal Hospitals, Old Airport Road, Bengaluru, India., Karthik HK; Department of Oncosurgery, Manipal Hospitals, Old Airport Road, Bengaluru, India., Prasad A; Department of Oncosurgery, Manipal Hospitals, Old Airport Road, Bengaluru, India., Islam H; Department of Oncosurgery, Manipal Hospitals, Old Airport Road, Bengaluru, India., Ashwin KR; Department of Oncosurgery, Manipal Hospitals, Old Airport Road, Bengaluru, India.
Jazyk:	angličtina
Zdroj:	European journal of breast health [Eur J Breast Health] 2022 Jul 01; Vol. 18 (3), pp. 271-278. Date of Electronic Publication: 2022 Jul 01 (Print Publication: 2022).
DOI:	10.4274/ejbh.galenos.2022.2022-2-5
Abstrakt:	Objective: The incidence of female breast cancer in the world is 11.7% with a mortality rate of 6.9%. According to Globocon 2020, breast cancer is the most commonly diagnosed cancer (24.5%) and the leading cause of cancer-related death amongst women worldwide. The purpose of this study was to analyze the impact of Body Mass Index (BMI) on pathological complete response (pCR) rates for operable breast cancer after neoadjuvant chemotherapy (NACT). The primary endpoint was to assess histopathological features of the surgical specimen in response to NACT and to investigate the relationship with pre-chemotherapy BMI taking into account the various molecular subtypes of breast cancer. Materials and Methods: Patients with biopsy-proven breast carcinoma who underwent surgery after NACT between January 2017 and May 2021 were included. All patients were initially divided into three groups depending on their pre-chemotherapy BMI. With BMI <22.9 as normal or underweight category, BMI of 23-27.4, was taken as overweight category and BMI ≥27.5 as obese category. Results: The study included 184 patients. Normal weight patients had the highest rate of pCR (75%) and the lowest was seen in the obese category (33.75%). Furthermore, the subtype most likely to achieve pCR was HER2+/ER negative followed by triple negative BC with odds ratios of 3.46 and 2.21, respectively. Conclusion: This retrospective study established that overweight and obese patients suffering from breast carcinoma had a lessened pCR rate following NACT in comparison with those who were under-/normal weight. Competing Interests: Conflict of Interest: No conflict of interest was declared by the authors. (©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF